All
Treating urinary tract infections can take time
July 1st 2003Signalment: Canine, Greyhound, 2.5 years old, female spayed, 65 lbs. Clinical history: The dog has a persistent urinary tract problem ? hematuria for at least one year according to the owner. The dog improves with antibiotics, but once finished, hematuria starts again. Therapy has included Clavamox.
Five-step process will help you develop vaccine protocols in your practice
July 1st 2003The recent publication of the new canine guidelines by the American Animal Hospital Association (AAHA) is creating some debate throughout the veterinary profession and has hit a little closer to home for even more practitioners.
Analyzing the risk and benefits for vaccinations
July 1st 2003There is a great deal of literature including many books on the science behind risk/benefit analysis. I reviewed some of them prior to writing this article, but try as I might, I could not incorporate much into the task at hand, namely doing a risk/benefit analysis of vaccination in pets.
Individualized assessment offers insight to patient's risk exposure to disease
July 1st 2003In the March/April issue of the Journal of the American Animal Hospital Association (AAHA), an Executive Summary of the 2003 Canine Vaccine Guidelines was published. A full text of the guidelines, recommendations, and supporting literature is available to AAHA members on the organization's Web site (www.aahanet.org).
Developing individualized vaccine protocols for your practice
July 1st 2003Developing vaccination protocols for cats and dogs used to seem like an exercise in futility. But now that the American Animal Hospital Association (AAHA) and the American Veterinary Medical Association (AVMA) have each published vaccination guidelines for these species the exercise has become more rewarding because practitioners can now use this information as a benchmark to tailor a specific program for each patient.
Schering-Plough gets Zubrin approval for osteoarthritis in dogs
July 1st 2003Schering-Plough Animal Health Corp. has received approval by the U.S. Food and Drug Administration (FDA) for Zubrin? (tepoxalin) rapidly-disintegrating tablets for the control of pain and inflammation associated with osteoarthritis in dogs.